Clinical trials: Degenerative Neurologic Disease
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Friedreich's Ataxia
A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World
In this study, researchers will learn more about a disease called Friedrich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their…
- Trial name
- NCT07887828
- Volunteers
- 40 people
- Sponsor
- Biogen
Lumbar Spinal Stenosis, Neuropathic Pain
Neuropathic Pain in Patients With Degenerative Lumbar Stenosis
Pre- and postoperative pain in patients with degenerative stenosis requires great attention, as it can mislead the doctor about treatment tactics.
- Conditions
- Lumbar Spinal Stenosis, Neuropathic Pain, Spinal Disease
- Trial name
- NCT06407167
- Testing
- DN4 (Douleur Neuropathique 4 Questions) questionnaire
- Where
- Russia
- Volunteers
- 147 people
- Sponsor
- N.N. Priorov National Medical Research Center of Traumatology and Orthopedics
Amyotrophic Lateral Sclerosis
An In-home Study of Brain Computer Interfaces
The investigators are developing a tool to help people who are severely paralyzed. This tool is called a brain-computer interface (BCI). BCIs can connect to computers or other electronic devices.
- Trial name
- NCT01123200
- Testing
- Brain Computer Interface for Wheelchair Tilt Control
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Myasthenia Gravis, Neuromuscular Disease
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S.
- Conditions
- Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
- Trial name
- NCT06866483
- Testing
- Social media recruitment, Self-Assessment, Follow-up
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ZS Associates
Huntington Disease
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
Cellavita-HD is a stem-cell therapy for Huntington's Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington's disease patients…
- Trial name
- ADORE-EXT (NCT04219241)
- Testing
- Cellavita-HD
- Where
- Brazil
- Volunteers
- 35 people
- Sponsor
- Azidus Brasil
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- NCT01421056
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 6 sites in United States, Italy
- Volunteers
- 74 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Alzheimer's Disease, Dementia
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
The purpose of this study is to evaluate the safety of 2 fixed doses of EVP-6124 hydrochloride (HCl) compared to placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease who are concurrently receiving stable…
- Conditions
- Alzheimer's Disease, Dementia, Cognition
- Trial name
- NCT02246075
- Testing
- EVP-6124
- Where
- 2 sites in United States
- Sponsor
- FORUM Pharmaceuticals Inc
Amyotrophic Lateral Sclerosis
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory…
- Trial name
- NCT04428775
- Testing
- ALZT-OP1a (cromolyn)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- AZTherapies, Inc.
Myotonic Dystrophy
DM1 Heart Registry - DM1 Respiratory Registry
Myotonic dystrophy type 1 (DM1) is the most frequent neuromuscular disease in adults. DM1 patients have an impaired prognosis (mean age of death <60 years) due to cardiac and respiratory complications.
- Trial name
- DM1-Heart-R (NCT01136330)
- Where
- France
- Volunteers
- 914 people
- Sponsor
- Institut de Myologie, France
Alzheimer Disease, Mild Cognitive Impairment
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
Purpose of clinical trial; This clinical trial is designed to evaluate the effectiveness of 'NeuroAI' prediction accuracy compared to the amyloid PET test results by retrospectively collecting medical data of patients with mild…
- Trial name
- NCT05383053
- Testing
- NeuroAI
- Where
- South Korea
- Volunteers
- 227 people
- Sponsor
- Neurozen Inc.
Huntington Disease
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
- Trial name
- NAC-preHD (NCT05509153)
- Testing
- NAC
- Where
- 5 sites in Australia
- Volunteers
- 160 people
- Sponsor
- Western Sydney Local Health District
Alzheimer Disease
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).
- Trial name
- NCT00285077
- Testing
- SR57667B
- Where
- 7 sites in Canada, Denmark and 5 more
- Volunteers
- 390 people
- Sponsor
- Sanofi
Healthy
REMINDer - A Digital Environmental Enrichment Intervention
The primary goal of this pilot study is to assess the feasibility and effectiveness for improving overall mental and physical well-being of a multimodal intervention program in older adults carried out in a digital telehealth…
- Trial name
- REMINDer (NCT06530277)
- Testing
- REMINDer (A digital environmental enrichment intervention)
- Where
- Germany
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Idiopathic Parkinson's Disease
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
Parkinson'disease is a neurodegenerative disorder characterised by bradykinesia, rigidity, rest tremor and postural instability.
- Trial name
- NCT00664157
- Testing
- Facial expression recognition of emotion
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Lumbar Spinal Stenosis, Lumbar Disc Herniation
Impact of Muscle Degeneration in Chronic Low Back Pain
Surgical interventions for the removal of intervertebral disc fragments or to enlarge a narrow spine canal are commonly performed worldwide and are considered efficient.
- Conditions
- Lumbar Spinal Stenosis, Lumbar Disc Herniation, Radiculopathy, Back Pain
- Trial name
- NCT04273828
- Testing
- Lumbar decompressive surgery
- Where
- Brazil
- Volunteers
- 168 people
- Sponsor
- Hospital Israelita Albert Einstein
Brain Injuries, Multiple Sclerosis
Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions
With an increase of over 38% in neurological related hospital admissions between 2008-13, there are now over 12.5 million cases of individuals with neurological conditions in the UK.
- Conditions
- Brain Injuries, Multiple Sclerosis, Parkinson Disease, Stroke
- Trial name
- NCT02454465
- Testing
- Acceptance and Commitment Therapy group
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University of Hertfordshire
Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder
This study tests whether enhancing deep sleep with gentle sounds at night can slow progression in people with iRBD or early Parkinson's disease. Participants wear a sensor headband and headphones for 18 months.
- Trial name
- SloW-iRBD (NCT07355842)
- Testing
- Tosoo Axora
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.